| Labcorp

November 1, 2017

Heart Failure with Preserved Ejection Fraction: A Therapeutic Brick Wall

In this webinar, Dr. Jon Plehn, MD, vice president of Cardiovascular Medicine at Covance will be joined by Dr.

November 27, 2017

Improving Clinical Outcomes In Impairment Studies

Industry standard timelines for end-to-end completion of a typical renal or hepatic impairment trial may be up to 18-22 months. Over the past 10 years, Covance has developed a built-for-purpose model for executing impairment studies resulting in a 36% reduction of time for end-to-end services.

February 22, 2018

Measles and Mumps, Forgotten Diseases of Recurring Relevance

? Drug development business of LabCorp ? World's most comprehensive drug development company ? Offers a consultative approach from biomarker discovery and assay development to global, multi-year trial execution in vaccines development

March 9, 2018

Leveraging Key Biomarkers to Advance Immuno-Oncology Drug Development and Find the Right Trial Participants

View this webinar to learn more about: ? Factors driving the importance of biomarkers in immuno-oncology development ? How to leverage key technologies - flow cytometry, immunohistochemistry and next-generation sequencing ? A real-world example of how to tackle the challenge of effective patient recruitment ?

March 21, 2018

Regenerative Medicine for Kidney Patients, Peripheral Artery Disease, and Beyond

Bioengineered blood vessels have great potential to improve the lives of hemodialysis patient. Gain a better understanding of the novel therapies in this growing field and the challenges faced to reach the market in this webinar.

May 11, 2018

Pediatric Clinical Trials in Diabetes: Challenges & Opportunities

What does it take to conduct an effective pediatric trial in diabetes in today's competitive landscape? From a lack of research infrastructure to the difficulties with determining inclusion/exclusion criteria, sponsors face many challenges in the process.